Thursday, April 2, 2026

Cardiogenic Shock

A 72-year-old man presents to the emergency department with severe chest pain and progressive shortness of breath for 4 hours. The pain is sudden in onset, substernal, crushing, radiates to the left arm and jaw, and is associated with diaphoresis, nausea, and vomiting. He has a history of hypertension, type 2 diabetes mellitus, ischemic heart disease, and heart failure with reduced ejection fraction, and is a current smoker with a 40-pack-year history. On examination, he appears pale, anxious, and diaphoretic. Blood pressure is 80/55 mmHg, heart rate is 118 beats/min, respiratory rate is 30 breaths/min, and oxygen saturation is 88% on room air. His extremities are cold and clammy with delayed capillary refill. Jugular venous pressure is elevated, and lung auscultation reveals bilateral basal crackles. Cardiac examination demonstrates an S3 gallop, and urine output is markedly reduced. Electrocardiography shows ST-segment elevation in leads V1 to V4. Laboratory evaluation reveals elevated cardiac troponin and a serum lactate of 5.2 mmol/L. Bedside echocardiography demonstrates severe LV systolic dysfunction with an ejection fraction of approximately 25% and anterior wall hypokinesis. Right heart catheterization shows a cardiac index of 1.7 L/min/m² and a pulmonary capillary wedge pressure of 24 mmHg. Diagnosis?

Diagnosis is acute anterior STEMI complicated by cardiogenic shock, with severe left ventricular pump failure and pulmonary congestion.

The combination of anterior STEMI, profound hypotension, cold extremities, oliguria, elevated lactate, severe LV systolic dysfunction, cardiac index 1.7 L/min/m², and PCWP 24 mmHg establishes a classic congested cardiogenic shock phenotype.

1. Definition

Cardiogenic shock is a clinical syndrome of inadequate systemic perfusion caused primarily by cardiac pump failure.

There is no single mandatory blood pressure or hemodynamic cutoff for all patients.

Typical findings include:

1.      Hypotension

1.      SBP <90 mmHg

2.      Or low MAP

3.      Or need for vasoactive support to maintain perfusion

2.      Evidence of end-organ hypoperfusion

1.      Cold extremities

2.      Delayed capillary refill

3.      Oliguria

4.      Altered mental status

5.      Elevated lactate

6.      Worsening renal or hepatic function

3.      When invasive hemodynamics are available:

1.      Cardiac index <2.2 L/min/m² supports low-output shock

2.      Elevated PCWP supports left-sided congestion

Cardiogenic shock can occasionally occur without overt hypotension, so systemic hypoperfusion is fundamental to the diagnosis.

2. Diagnosis in This Patient

This patient has multiple features of cardiogenic shock:

1.      SBP 80 mmHg

2.      Cold and clammy extremities

3.      Delayed capillary refill

4.      Marked oliguria

5.      Lactate 5.2 mmol/L

6.      Cardiac index 1.7 L/min/m²

7.      PCWP 24 mmHg

8.      LVEF approximately 25%

9.      Pulmonary crackles

10.  Acute anterior STEMI

This is a cold and wet cardiogenic shock phenotype, reflecting both hypoperfusion and congestion.

The anterior STEMI pattern in leads V1 to V4 most strongly suggests an LAD culprit lesion.

3. Etiology

Important causes of cardiogenic shock include:

3.1 Acute Myocardial Infarction

AMI is a major cause of cardiogenic shock.

Mechanisms include:

1.      Extensive LV myocardial injury

2.      RV infarction

3.      Ischemia-induced severe ventricular dysfunction

4.      Mechanical complications

5.      Malignant arrhythmias

3.2 Acute or Acute-on-Chronic Heart Failure

Severe decompensated systolic or diastolic dysfunction can produce cardiogenic shock even without acute MI.

3.3 Mechanical Complications of MI

These must be actively excluded:

1.      Ventricular septal rupture

2.      Papillary muscle rupture causing acute severe mitral regurgitation

3.      LV free-wall rupture with tamponade

An abrupt new murmur or sudden hemodynamic deterioration should immediately raise concern for a mechanical complication.

3.4 Other Causes

1.      Fulminant myocarditis

2.      Severe acute valvular disease

3.      Takotsubo syndrome

4.      Massive RV infarction

5.      Tachyarrhythmias

6.      Severe bradyarrhythmias

Other causes of shock that may mimic or coexist with cardiogenic shock, such as cardiac tamponade, should also be considered. Tamponade is conventionally classified as obstructive shock, even when it results from post-MI free-wall rupture.

4. Pathophysiology

In AMI-related cardiogenic shock:

1.      Extensive myocardial ischemia causes reduced contractility.

2.      Stroke volume and cardiac output fall.

3.      Systemic arterial pressure declines.

4.      Coronary perfusion may decrease further.

5.      Neurohormonal activation causes:

1.      Sympathetic vasoconstriction

2.      Increased systemic vascular resistance

3.      RAAS activation

4.      Sodium and water retention

6.      Increased afterload further impairs LV ejection.

7.      Elevated LV filling pressure causes:

1.      Pulmonary venous congestion

2.      Pulmonary edema

3.      Hypoxemia

8.      Progressive tissue hypoperfusion produces:

1.      Lactic acidosis

2.      Acute kidney injury

3.      Hepatic injury

4.      Altered mental status

5.      Multiorgan failure

This creates a self-perpetuating cycle of ischemia, pump failure, hypoperfusion, and organ dysfunction.

5. Hemodynamic Profile

Typical LV-predominant congested cardiogenic shock is characterized by:

1.      Reduced cardiac output or cardiac index

2.      Elevated LV filling pressure or PCWP

3.      Increased systemic vascular resistance may occur

4.      Pulmonary congestion

This patient has:

1.      Cardiac index 1.7 L/min/m²

2.      PCWP 24 mmHg

These findings demonstrate low cardiac output with markedly elevated left-sided filling pressure.

A complete invasive hemodynamic assessment can also help distinguish:

1.      LV-predominant shock

2.      RV-predominant shock

3.      Biventricular shock

6. SCAI Shock Classification

The SCAI classification describes cardiogenic shock severity dynamically.

Stage A: At Risk

1.      At risk for shock

2.      No current hypotension or hypoperfusion

Stage B: Beginning Shock

1.      Hemodynamic instability

2.      Hypotension or tachycardia

3.      No systemic hypoperfusion

Stage C: Classic Shock

1.      Systemic hypoperfusion

2.      Often hypotension

3.      Requires pharmacologic or mechanical support beyond simple volume correction

Typical findings include:

1.      Cold extremities

2.      Oliguria

3.      Lactate ≥2 mmol/L

4.      Cardiac index <2.2 L/min/m² when measured

Stage D: Deteriorating Shock

1.      Stage C physiology that fails to improve with initial therapy

2.      Rising lactate

3.      Worsening organ perfusion

4.      Escalating vasoactive or mechanical support

Stage E: Extremis

1.      Actual or impending circulatory collapse

2.      Profound refractory hypotension

3.      Severe metabolic derangement

4.      Cardiac arrest or near-arrest physiology

This patient's initial presentation is consistent with SCAI Stage C cardiogenic shock.

Stage D should not be assigned solely because the lactate is 5.2 mmol/L. Stage D requires evidence that the patient is deteriorating or failing to respond after an initial therapeutic intervention.

Shock stage should be reassessed repeatedly, because trajectory is highly prognostic.

7. Diagnostic Evaluation

7.1 ECG

The ECG identifies the ischemic territory and guides emergency reperfusion.

This patient has:

ST elevation in V1 to V4 = acute anterior STEMI, usually involving the LAD.

7.2 Cardiac Troponin

1.      Elevated cardiac troponin indicates myocardial injury.

2.      A rise and/or fall in troponin supports acute myocardial injury.

3.      In a patient with diagnostic STEMI, reperfusion should not be delayed while awaiting serial biomarker measurements.

7.3 Bedside Echocardiography

Urgent echocardiography evaluates:

1.      LV systolic function

2.      RV function

3.      Regional wall-motion abnormalities

4.      Acute mitral regurgitation

5.      Ventricular septal rupture

6.      Pericardial effusion or tamponade

7.      Other causes of shock

Echocardiography should not delay emergency coronary reperfusion.

7.4 Laboratory Monitoring

Important tests include:

1.      Serial lactate

2.      Renal function

3.      Electrolytes

4.      Liver enzymes

5.      Acid-base status

6.      Complete blood count

7.      Coagulation profile

8.      Serial cardiac biomarkers

The trend in lactate and organ function is more useful than a single measurement.

7.5 Invasive Hemodynamics

Pulmonary artery catheterization is not mandatory for every patient with cardiogenic shock.

However, invasive hemodynamic monitoring can be useful in selected patients to:

1.      Define the shock phenotype

2.      Quantify congestion

3.      Assess RV and LV function

4.      Guide vasoactive therapy

5.      Select temporary mechanical circulatory support

6.      Assess response to therapy

7.      Guide device escalation and weaning

Invasive hemodynamic assessment should not delay emergency culprit-vessel revascularization.

8. Cardiac Power Output

Cardiac power output is calculated as:

CPO = (MAP × cardiac output) / 451

and is expressed in watts.

Low CPO is associated with adverse prognosis.

1.      The SHOCK registry identified a CPO of approximately ≤0.53 W as a threshold associated with increased mortality.

2.      A value <0.6 W is commonly used clinically as a marker of high-risk hemodynamic compromise.

3.      CPO should not be interpreted in isolation.

4.      CPO should not be used as the sole diagnostic criterion for cardiogenic shock.

5.      CPO should not serve as the sole trigger for mechanical circulatory support.

Cardiac output, rather than cardiac index, is required for the standard CPO calculation.

9. Immediate Management

Management should proceed simultaneously with diagnosis.

Priorities include:

1.      Immediate coronary reperfusion

2.      Restoration of systemic perfusion

3.      Treatment of hypoxemia

4.      Identification of mechanical complications

5.      Serial reassessment of shock severity

A multidisciplinary shock team should be activated early when available.

9.1 Oxygen and Ventilatory Support

This patient has an oxygen saturation of 88%, so supplemental oxygen is indicated.

If pulmonary edema and respiratory distress worsen:

1.      Escalate respiratory support as needed.

2.      Noninvasive positive-pressure ventilation may benefit selected patients with cardiogenic pulmonary edema if hemodynamics permit, but profound hypotension limits its use because positive pressure can reduce preload and worsen hemodynamics.

3.      Positive-pressure ventilation can also reduce LV afterload, so its overall hemodynamic effect depends on preload dependence, RV function, ventilatory pressures, and the clinical phenotype.

4.      Endotracheal intubation may be required for severe respiratory failure, but induction and positive-pressure ventilation can worsen shock and should be performed with careful hemodynamic preparation.

9.2 Volume Management

This patient has:

1.      Elevated JVP

2.      Pulmonary crackles

3.      PCWP 24 mmHg

Therefore:

Routine IV fluid boluses should be avoided.

He is already congested.

Volume therapy should be guided by clinical and hemodynamic assessment rather than administered empirically.

10. Vasoactive Therapy

Vasoactive drugs should be used at the lowest effective dose for the shortest necessary duration.

10.1 Norepinephrine

For most patients with cardiogenic shock and significant hypotension:

Norepinephrine is a reasonable initial vasoactive agent.

It can:

1.      Increase MAP

2.      Improve coronary and systemic perfusion pressure

3.      Provide modest beta-adrenergic inotropic support

No single vasoactive agent has demonstrated a definitive mortality advantage in all cardiogenic-shock populations.

10.2 Inotropes

If cardiac output remains inadequate after achieving a reasonable perfusion pressure, an inotrope may be added.

Options include:

1.      Dobutamine

2.      Milrinone

Dobutamine:

1.      Increases contractility

2.      May increase cardiac output

3.      Can cause tachyarrhythmias and hypotension

Milrinone:

1.      Increases contractility

2.      Reduces afterload

3.      Can cause significant hypotension

4.      Has a longer half-life

5.      Is renally cleared and should be used cautiously with renal dysfunction

In this profoundly hypotensive patient, milrinone would generally be less attractive as an initial agent.

11. Definitive Treatment of AMI-Related Cardiogenic Shock

Emergency culprit-vessel revascularization is the foundational Class I treatment with established survival benefit in AMI-related cardiogenic shock.

In selected patients with STEMI and severe or refractory cardiogenic shock, a microaxial flow pump is also reasonable to reduce mortality.

This patient requires:

Immediate coronary angiography with primary PCI of the culprit artery.

If PCI is not feasible because of coronary anatomy or technical considerations, emergency CABG may be required when appropriate.

For STEMI complicated by cardiogenic shock and multivessel coronary disease:

1.      Routine immediate multivessel PCI is not recommended.

2.      The initial strategy should generally be culprit-vessel PCI only.

3.      Additional revascularization can be considered later according to anatomy, residual ischemia, and clinical stability.

12. Antithrombotic Therapy

Treatment should follow contemporary STEMI and PCI protocols, adjusted for bleeding risk and planned mechanical support.

Typical therapy includes:

1.      Aspirin

2.      A P2Y12 inhibitor

3.      Procedural anticoagulation

Shock can impair gastrointestinal absorption of oral medications, so antiplatelet strategy may need individualization in critically ill or mechanically ventilated patients.

13. Mechanical Circulatory Support

Temporary mechanical circulatory support should not be used routinely in every patient with cardiogenic shock.

Device selection should be individualized according to:

1.      Shock severity

2.      LV versus RV failure

3.      Respiratory failure

4.      Mechanical complications

5.      Vascular anatomy

6.      Bleeding risk

7.      Response to initial pharmacologic therapy

8.      Institutional expertise

13.1 Microaxial Flow Pump

A microaxial flow pump such as Impella CP provides:

1.      LV unloading

2.      Increased forward flow

3.      Reduced LV filling pressure

The DanGer-Shock trial demonstrated lower 180-day mortality with a microaxial flow pump plus standard care compared with standard care alone in selected patients with STEMI-related cardiogenic shock.

However:

1.      Severe adverse events were substantially more frequent.

2.      Major bleeding and limb ischemia are important risks.

3.      Renal replacement therapy was more frequent in the device group.

4.      The trial population was highly selected.

Therefore, contemporary ACS guidance considers a microaxial flow pump reasonable in selected patients with STEMI and severe or refractory cardiogenic shock to reduce mortality.

It should not be interpreted as mandatory therapy for every patient with AMI-CS.

13.2 Intra-Aortic Balloon Pump

Routine IABP use in AMI-related cardiogenic shock:

Does not improve survival and is not recommended routinely.

It may still have a role in selected situations, particularly as short-term stabilization in some patients with mechanical complications.

13.3 VA-ECMO

Routine VA-ECMO for AMI-related cardiogenic shock has not demonstrated a survival benefit and is not recommended routinely.

VA-ECMO may still be considered as rescue support in carefully selected patients with refractory circulatory collapse, particularly when there is:

1.      Severe biventricular failure

2.      Severe hypoxemia

3.      Cardiac arrest

4.      Potentially reversible disease

5.      A bridge to another definitive therapy

VA-ECMO can increase LV afterload, so LV unloading may be required in selected patients.

13.4 Mechanical Complications

When cardiogenic shock results from:

1.      Ventricular septal rupture

2.      Papillary muscle rupture

3.      Other major mechanical complications

Temporary mechanical support may be reasonable as a bridge to definitive surgical or structural intervention.

14. Congestion Management

Once systemic perfusion pressure has been stabilized:

1.      Persistent pulmonary congestion should be treated.

2.      Loop diuretics may be used when adequate perfusion is present.

3.      Diuresis must be balanced against the risk of further reducing cardiac output.

The immediate priority in this patient remains revascularization and restoration of perfusion.

15. Monitoring

Frequent reassessment should include:

1.      Blood pressure and MAP

2.      Heart rate and rhythm

3.      Mental status

4.      Capillary refill

5.      Urine output

6.      Lactate trend

7.      Renal and hepatic function

8.      Acid-base status

9.      Oxygenation

10.  Pulmonary congestion

11.  Echocardiographic findings

12.  Invasive hemodynamics when indicated

13.  Serial SCAI shock stage

Failure of lactate to clear, worsening oliguria, progressive acidosis, or escalating vasoactive requirements should prompt urgent reassessment and consideration of escalation of support.

16. Complications

AMI-related cardiogenic shock may cause:

1.      Multiorgan failure

2.      Acute kidney injury

3.      Ischemic hepatitis

4.      Lactic acidosis

5.      Pulmonary edema

6.      Respiratory failure

7.      Ventricular arrhythmias

8.      Bradyarrhythmias

9.      Mechanical complications of MI

10.  Cardiac arrest

11.  Death

Temporary mechanical support may additionally cause:

1.      Major bleeding

2.      Limb ischemia

3.      Hemolysis

4.      Vascular injury

5.      Infection

6.      Stroke

7.      Device-related complications

17. Prognosis

Cardiogenic shock remains a high-mortality condition.

Poor prognostic features include:

1.      Advanced age

2.      Persistent or rising lactate

3.      Severe renal dysfunction

4.      Multiorgan failure

5.      Cardiac arrest

6.      Severe biventricular failure

7.      Persistent hypotension

8.      Failure to improve with initial therapy

9.      Progression to higher SCAI shock stages

Early recognition, rapid culprit-vessel reperfusion, repeated shock staging, and individualized hemodynamic support are critical.

18. Key Clinical Insight

Acute MI + hypotension + systemic hypoperfusion = cardiogenic shock until proven otherwise.

For this patient:

Anterior STEMI + SBP 80 mmHg + cold extremities + oliguria + lactate 5.2 mmol/L + CI 1.7 L/min/m² + PCWP 24 mmHg = acute MI-related congested cardiogenic shock.

The immediate priorities are:

1.      Emergency culprit-vessel PCI

2.      Oxygen for hypoxemia

3.      Norepinephrine when vasoactive support is required

4.      Inotropic support when cardiac output remains inadequate

5.      Rapid exclusion of mechanical complications

6.      Serial SCAI shock staging

7.      Selective, not routine, use of temporary mechanical circulatory support

References

1.      Sinha SS, Morrow DA, Kapur NK, Kataria R, Roswell RO. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock. J Am Coll Cardiol. 2025;85(16):1618-1641. doi:10.1016/j.jacc.2025.02.018.

2.      Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151(13):e771-e862. doi:10.1161/CIR.0000000000001309.

3.      Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies. J Am Coll Cardiol. 2022;79(9):933-946. doi:10.1016/j.jacc.2022.01.018.

4.      Møller JE, Engstrøm T, Jensen LO, et al. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med. 2024;390(15):1382-1393. doi:10.1056/NEJMoa2312572.

No comments:

Post a Comment